Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development FDAThe U.S.RegulatoryGene Therapy PlatformRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) FDA The U.S. RegulatoryGene Therapy PlatformRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA renews criticism of trial sponsors over transparencyNext: Lilly investing billions to prepare for overseas oral GLP-1 launches Related Stories Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026 Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026 Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
